<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383756</url>
  </required_header>
  <id_info>
    <org_study_id>UDWBBT</org_study_id>
    <nct_id>NCT04383756</nct_id>
  </id_info>
  <brief_title>Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation</brief_title>
  <official_title>Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the
      solid organ donor. These 20 patients will be compared to 20 historical matched controls with
      regards to allogenic blood product usage and other physiologic markers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 recipients receive donor whole blood 20 historic match controls are compared to the 20 study participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use of allogenic banked blood products</measure>
    <time_frame>perioperative up to 72 hours post operative</time_frame>
    <description>Measured by the number of allogenic banked blood products used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Economic cost</measure>
    <time_frame>perioperative up to 72 hours post operative</time_frame>
    <description>Total cost of perioperative transfusions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to discharge (approximately 4-5 days)</time_frame>
    <description>Number of deaths, life-threatening events, hospitalizations, disabilities or permanent damage, or congenital anomalies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Transfusion Related Complication</condition>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Donor Blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Banked Blood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor Blood</intervention_name>
    <description>Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood</description>
    <arm_group_label>Donor Blood</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Banked Blood</intervention_name>
    <description>Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)</description>
    <arm_group_label>Banked Blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Recipients 18 years or older.

          -  Deceased donor whole graft liver transplant recipients undergoing liver transplant
             starting 07/01/2020 and onwards at VUMC.

          -  ABO-matched recipient and donor.

          -  Donor Hb level &gt;/= 8 g/dL

          -  Recipients with negative ABO antibody screen

        Exclusion Criteria:

          -  - Pediatric recipient.

          -  HBS Antigen+ donors

          -  HCV NAT+ donors

          -  Donors of A2 blood type

          -  Donors on oral anticoagulants (except for aspirin) over the past 3 days before organ
             procurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clayne Benson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clayne Benson, MD</last_name>
    <phone>615-343-6268</phone>
    <email>clayne.benson@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Clayne Benson</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Cardiothoracic Anesthesia and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

